The funding of Biopharmaceutical Research and Development provides a comprehensive critical review of the funding of research and development (R&D) in the human biopharmaceutical market. It addresses private and public funding sources available in the US and internationally. The biopharmaceutical market is among the most research-intensive market sectors globally. Clinical researchers face a multitude of public and private funding options in going to market. These funding options are continually changing and complex and are expected to decrease in the near future. A lack of understanding of the scale, scope, and inner workings of R&D funding can, at times, act as a barrier and slow down or even eliminate the R&D process. The book lessens these barriers by describing the theoretical underpinnings, present practice, and trends in R&D funding in the US and internationally. It includes a review and discussion of public-private partnership activity, noting the complementary relationship between public and private funding. The book also contains an overview of the inner-workings of strategic alliance activity, including advantages and disadvantages for each party. It provides an outline of venture capital activity, detailing methods by which venture capital firms raise capital and are organized and a description of the venture capital-entrepreneur arrangement and its effects. The book also presents an overview of the IPO process and the fates of firms going public.